WAM
ALXN

Wolverine Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Wolverine Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-5,900
Closed -$717K – 1543
2017
Q2 		$717K Hold
5,900
– – 0.01% 701
2017
Q1 		$715K Buy
+5,900
New +$761K 0.01% 618
2014
Q4 		– Sell
-183
Closed -$72K – 2595
2014
Q3 		$72K Buy
+183
New +$30.1K ﹤0.01% 1418
2014
Q1 		– Sell
-200
Closed -$417K – 2879
2013
Q4 		$417K Sell
200
-50
-20% -$6K 0.01% 845
2013
Q3 		$248K Buy
250
+46
+23% +$5.05K 0.01% 1067
2013
Q2 		$90K Buy
+204
New +$19.7K ﹤0.01% 1468

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Wolverine Asset Management's ALXN Position: Q3 2021 in Review

Wolverine Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 37,926 shares — an estimated $6.97M sold.

Wolverine Asset Management first reported a position in ALXN in Q2 2013 and held it in 14 quarters. The position peaked at $6.97M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Wolverine Asset Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Wolverine Asset Management sold 37,926 Alexion Pharmaceuticals shares in Q3 2021, an estimated $6.97M.
  • Wolverine Asset Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 14 quarters.
  • Wolverine Asset Management's Alexion Pharmaceuticals position peaked at $6.97M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Wolverine Asset Management's 13F filing for Q3 2021, filed 12 Nov 2021.